Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme - Trial NCT01062399
Access comprehensive clinical trial information for NCT01062399 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by Radiation Therapy Oncology Group and is currently Completed. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 279 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Radiation Therapy Oncology Group
Timeline & Enrollment
Early Phase 1
Dec 01, 2010
May 20, 2022
Primary Outcome
Phase I: Number of Patients With Dose-limiting Toxicity (DLT),Phase II: Progression-free Survival (PFS)
Summary
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes
 needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,
 such as temozolomide, work in different ways to stop the growth of tumor cells, either by
 killing the cells or by stopping them from dividing. Radiation therapy uses high energy
 x-rays to kill tumor cells. Giving everolimus together with temozolomide and radiation
 therapy may kill more tumor cells.
 
 PURPOSE: This phase I/II trial is studying the side effects and best dose of everolimus when
 given together with temozolomide and radiation therapy and to see how well it works in
 treating patients with newly diagnosed glioblastoma multiforme.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01062399
Non-Device Trial